Nathalie Bonnet

Clermont-ferrand, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome.

Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome.

Journal: The British journal of dermatology

Published: March 13, 2026

Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.

Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.

Journal: EClinicalMedicine

Published: December 25, 2024

Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.

Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.

Journal: EClinicalMedicine

Published: February 20, 2024

Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study).

Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study).

Journal: The British journal of dermatology

Published: January 14, 2024

Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.

Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.

Journal: Frontiers in immunology

Published: July 01, 2022

ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells.

ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 15, 2021

Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group.

Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group.

Journal: Clinical and experimental dermatology

Published: May 10, 2021

ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.

ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.

Journal: Blood advances

Published: May 19, 2020

HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma.

HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma.

Journal: Blood

Published: February 02, 2020

Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.

Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 09, 2019

Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database.

Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database.

Journal: The British journal of dermatology

Published: March 06, 2019

Desensitization protocol for angio-oedema induced by encorafenib in a patient with metastatic melanoma.

Desensitization protocol for angio-oedema induced by encorafenib in a patient with metastatic melanoma.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 06, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026